Bevacizumab + atezolizumab for fatty liver

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 24 Oct 2023: Trial registered, NCT06096779
  2. 15 Jul 2024: Trial started, NCT06096779

The trials

NCT06096779: A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

State
Under way
Phase
Phase 2
People
30 taking part
Started
15 Jul 2024
Primary completion
30 Jul 2027
Arms
Cohort A: Atezolizumab+Bevacizumab
Results
None posted
  1. 24 Oct 2023: Trial registered
  2. 15 Jul 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.